FOXM1 and neoplasm: The involvement of FAK in FOXM1-driven OC stemness is relevant given the many clinical trials that are assessing FAK inhibition in different tumor types including OC (https://clinicaltrials.gov/search?cond=ovariancancer&intr=Defactinib).